Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801
Dateline City:
KENILWORTH, N.J. & MIAMI
Clinical Studies of EIDD-2801 for the Treatment of Patients with COVID-19 are Underway
KENILWORTH, N.J. & MIAMI–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics LP, a closely held biotechnology company, today announced that the companies have entered into a collaboration agreement to develop EIDD-2801, an orally available antiviral candidate currently in early clinical development for the treatment of patients with COVID-19.
Language:
English
Contact:
Merck Media:
Patrick Ryan
+1 (201) 452-2409
Ian McConnell
+1 (973) 901-5722
Merck Investors:
Peter Dannenbaum
+1 (908) 740-1037
Michael DeCarbo
+1 (908) 740-1807
Ridgeback Bio
Media +1 (786) 687-2493
Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck
